TGFBR1 (Ab-165) Antibody

What is TGFBR1 (Ab-165) Antibody and what epitope does it recognize?

TGFBR1 (Ab-165) Antibody is a polyclonal antibody specifically designed to recognize the serine 165 region of the Transforming Growth Factor Beta Receptor 1 (TGFBR1). This antibody is generated using a synthesized non-phosphopeptide derived from Human TGF beta Receptor I, specifically targeting the region around the phosphorylation site of serine 165 (D-P-S(p)-L-D) . The antibody is typically produced in rabbits and purified using affinity-chromatography with epitope-specific immunogen to ensure high specificity and minimal cross-reactivity with other proteins .

What are the primary applications for TGFBR1 (Ab-165) Antibody in research?

The TGFBR1 (Ab-165) Antibody has multiple validated research applications:

This antibody is most commonly employed in studies investigating TGF-β signaling pathways, which regulate diverse cellular processes including proliferation, differentiation, and apoptosis .

What species reactivity has been confirmed for TGFBR1 (Ab-165) Antibody?

The TGFBR1 (Ab-165) Antibody has been validated for reactivity with:

• Human (primary reactivity)

• Mouse (cross-reactivity confirmed)

Some variants may also react with rat samples, though this should be experimentally verified before use in critical experiments . When using the antibody with species other than human, it is advisable to perform preliminary validation tests to confirm specificity and optimal working conditions.

How does the TGF-beta signaling pathway function, and what role does TGFBR1 play?

TGFBR1 is a transmembrane serine/threonine kinase that forms a heteromeric complex with type II TGF-beta receptors (TGFBR2) when bound to TGF-beta ligands. The signaling cascade proceeds as follows:

• TGF-β ligand (TGFB1, TGFB2, or TGFB3) binds to TGFBR2

• TGFBR2 dimerizes with and phosphorylates TGFBR1, activating its kinase domain

• Activated TGFBR1 phosphorylates downstream SMAD proteins (SMAD2/3)

• Phosphorylated SMADs form complexes with SMAD4 and translocate to the nucleus

• The SMAD complex regulates transcription of target genes

This pathway regulates numerous physiological processes including cell cycle arrest, mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, and immunosuppression . TGFBR1 is also involved in non-canonical, SMAD-independent pathways that contribute to processes like epithelial-to-mesenchymal transition and apoptosis .

How can TGFBR1 (Ab-165) Antibody be optimized for Western blotting protocols?

Optimizing Western blotting with TGFBR1 (Ab-165) Antibody requires careful attention to several parameters:

Sample Preparation:

• Include phosphatase inhibitors in lysis buffers to preserve Ser165 phosphorylation status

• Use fresh samples when possible, as freeze-thaw cycles can affect phospho-epitope integrity

• Consider enrichment steps for membrane proteins to improve detection sensitivity

Protocol Optimization:

• Blocking: 5% BSA in TBST is generally preferred over milk-based blockers (which contain phosphatases)

• Primary antibody dilution: Start with 1:1000 and adjust based on signal strength

• Incubation time: Overnight at 4°C often yields better results than shorter incubations

• Secondary antibody: Anti-rabbit IgG with appropriate conjugation (HRP is common)

• Detection method: ECL substrates with varying sensitivity depending on expected expression levels

For detecting phosphorylated TGFBR1, consider using phospho-specific antibody variants like those targeting pSer165 specifically, which provide more precise information about the receptor's activation state .

What controls should be included when using TGFBR1 (Ab-165) Antibody for experimental validation?

Rigorous experimental design requires appropriate controls to validate TGFBR1 (Ab-165) Antibody results:

Positive Controls:

• Cell lines with confirmed TGFBR1 expression (HepG2, NIH-3T3)

• TGF-β stimulated cells (increases receptor activation)

• Recombinant TGFBR1 protein (for antibody validation)

Negative Controls:

• TGFBR1 knockout or knockdown samples (e.g., TGFBR1 CKO tissues as described in source )

• Secondary antibody-only controls (to assess non-specific binding)

• Blocking peptide competition assays (to confirm epitope specificity)

Validation Controls:

• Use of multiple TGFBR1 antibodies targeting different epitopes (for confirmation)

• Phosphatase treatment (to verify phospho-specificity)

• TGF-β receptor inhibitors like SB431542 (to confirm signaling specificity)

How can researchers differentiate between TGFBR1 and other TGF-beta receptor family members in their experiments?

Differentiating between TGF-beta receptor family members requires strategic experimental design:

Antibody Selection Strategy:

• Choose antibodies targeting unique regions not conserved among family members

• The Ser165 region of TGFBR1 contains sequences distinct from ACVR1B and other family members

Experimental Approaches:

• Western blotting: Differentiate based on molecular weight (TGFBR1: ~56 kDa vs. other family members)

• RT-qPCR: Design primers specific to unique regions of TGFBR1 mRNA

• Immunoprecipitation followed by mass spectrometry: For definitive protein identification

• Functional studies: Use selective inhibitors or ligands (TGF-β1 primarily signals through TGFBR1/TGFBR2)

Analysis Considerations:

• Compare expression patterns across tissues (different receptors have distinct expression profiles)

• Examine co-immunoprecipitation with known specific binding partners

• Assess downstream signaling events unique to each receptor pathway

Studies investigating both TGFBR1 and ACVR1B (as in source ) demonstrate the importance of receptor-specific approaches to understand their distinct and synergistic roles in biological processes .

What methodological approaches help resolve conflicting data when studying TGFBR1 phosphorylation status?

When confronting conflicting data regarding TGFBR1 phosphorylation status, employ the following methodological approaches:

Common Sources of Discrepancy:

• Antibody cross-reactivity with other phosphorylated proteins

• Differences in sample preparation affecting phosphorylation preservation

• Temporal dynamics of phosphorylation missed by single-timepoint analyses

• Cell type-specific expression levels and phosphorylation patterns

Resolution Strategies:

• Complementary techniques: Combine Western blotting with immunoprecipitation, mass spectrometry, or phospho-proteomics

• Kinase assays: Direct measurement of TGFBR1 kinase activity

• Time-course experiments: Capture dynamic phosphorylation events

• Phospho-specific vs. total TGFBR1 antibodies: Compare ratios rather than absolute values

• Site-directed mutagenesis: Create S165A mutants to confirm specificity

Analysis Framework:

• Document all experimental conditions meticulously

• Consider phosphatase treatment controls

• Validate with genetic approaches (knockdown/knockout)

• Examine downstream effects (SMAD2/3 phosphorylation) as functional readouts

Research on TGFBR1 in different experimental systems has revealed context-dependent phosphorylation patterns, emphasizing the need for comprehensive validation strategies .

How is TGFBR1 (Ab-165) Antibody used to investigate TGF-beta signaling in fibrosis and tissue regeneration?

TGFBR1 (Ab-165) Antibody serves as a valuable tool for investigating TGF-beta's central role in fibrosis and tissue regeneration:

Fibrosis Research Applications:

• Detecting TGFBR1 activation in fibrotic tissues

• Monitoring changes in receptor expression during disease progression

• Assessing the efficacy of anti-fibrotic therapies targeting the TGF-beta pathway

Tissue Regeneration Studies:

• Tracking TGFBR1 involvement in wound healing processes

• Investigating receptor dynamics during tissue repair

• Evaluating the impact of TGFBR1 mutations on regenerative capacity

The role of TGFBR1 in these processes is highlighted by research showing that a single base change in the TGFBR1 gene can accelerate wound healing in slow-healing mouse strains. These studies utilized TGFBR1 detection methods to demonstrate that the R244Q variant receptor had a twofold increase in activity compared to wild-type, offering insights into potential therapeutic targets for enhanced wound healing .

What protocols are recommended for studying TGFBR1 in knockout/conditional knockout animal models?

When studying TGFBR1 in knockout or conditional knockout models, researchers should implement the following specialized protocols:

Genotyping and Validation:

• PCR-based genotyping to confirm gene deletion

• RT-qPCR to verify reduced TGFBR1 mRNA expression (expect 80-97% reduction in successful knockouts)

• Western blotting with TGFBR1 antibodies to confirm protein reduction

• Immunohistochemistry to assess tissue-specific deletion patterns

Experimental Considerations:

• Account for TGFBR1 expression by non-targeted cell types within tissues

• Implement cell-type specific markers to distinguish knockout effects

• Use Cre-loxP systems with appropriate promoters (e.g., Amhr2-Cre for reproductive tract studies)

• Include littermate controls without Cre recombinase

Phenotypic Analysis:

• Document developmental effects (TGFBR1 is essential for female reproductive tract integrity)

• Assess tissue regeneration capacity (muscle regeneration is affected by TGFBR1 knockout)

• Measure collagen deposition and fibroblast marker expression (Tcf4, Pdgfra)

• Examine pathway activity through phospho-SMAD levels

Research has demonstrated that TGFBR1 knockout in specific tissues yields distinctive phenotypes, such as infertility in female reproductive tract-specific knockouts and altered myofiber regeneration in muscle-specific knockouts .

How can researchers effectively use TGFBR1 (Ab-165) Antibody to study cross-talk between TGF-beta and other signaling pathways?

Studying signaling cross-talk with TGFBR1 (Ab-165) Antibody requires sophisticated experimental designs:

Co-immunoprecipitation Approaches:

• Immunoprecipitate TGFBR1 and probe for components of other pathways

• Perform reverse co-IP with partners from intersecting pathways

• Analyze phosphorylation-dependent interactions using phospho-specific antibodies

Multiplexed Detection Methodologies:

• Simultaneous immunofluorescence with antibodies to multiple pathway components

• Multiplex Western blotting to detect pathway activation markers

• Phospho-flow cytometry for single-cell pathway activation analysis

Functional Cross-talk Assessment:

• Selective pathway inhibition followed by TGFBR1 activation measurement

• Combinatorial stimulation with multiple pathway ligands

• Time-course experiments to determine sequential pathway activation

Recent research has uncovered important cross-talk between NPC1 (involved in cholesterol transport) and TGFBR1 stability regulation. NPC1 was found to promote TGF-β signaling by preventing proteasome-mediated degradation of TGFBR1 through inhibition of Lys 48-linked ubiquitination, demonstrating a novel regulatory mechanism independent of cholesterol transport .

What are the methodological considerations for using TGFBR1 (Ab-165) Antibody in cancer research applications?

Cancer research applications of TGFBR1 (Ab-165) Antibody require specialized methodologies:

Tissue Microarray (TMA) Analysis:

• Score TGFBR1 expression intensity (0-3 scale) and percentage of positive cells (0-4 scale)

• Calculate immunoreactive scores (0-12) by multiplying intensity and percentage scores

• Compare expression between tumor and adjacent normal tissues

• Correlate with clinicopathological parameters and patient outcomes

Cell Line-Based Investigations:

• Compare TGFBR1 expression and phosphorylation across cancer cell lines

• Assess receptor stability and degradation pathways using proteasome/lysosome inhibitors

• Evaluate ubiquitination patterns (Lys48 vs. Lys63-linked) that influence receptor fate

• Correlate with invasive/metastatic potential

Functional Studies:

• Use TGFBR1 inhibition/activation to assess effects on proliferation, migration, EMT

• Examine downstream signaling through canonical (SMAD) and non-canonical pathways

• Study context-dependent tumor-promoting vs. tumor-suppressive effects

Research has demonstrated that NPC1 significantly promotes hepatocellular carcinoma progression by modulating the TGF-β pathway through TGFBR1 stabilization, identifying a potential therapeutic vulnerability for this cancer type .

What are common sources of false-positive and false-negative results when using TGFBR1 (Ab-165) Antibody, and how can they be mitigated?

Recognizing and addressing potential artifacts is essential for reliable TGFBR1 antibody results:

Common Sources of False-Positives:

• Cross-reactivity with related receptors (especially other TGF-β superfamily members)

• Non-specific binding to denatured proteins in fixed tissues

• Secondary antibody binding to endogenous immunoglobulins

• High background due to inappropriate blocking

Mitigation Strategies for False-Positives:

• Validate antibody specificity using knockout/knockdown controls

• Include peptide competition controls

• Optimize blocking conditions (5% BSA often preferred)

• Titrate antibody concentration carefully

Common Sources of False-Negatives:

• Insufficient antigen retrieval (for IHC/IF)

• Epitope masking by protein interactions

• Loss of phosphorylation during sample processing

• Low expression levels below detection threshold

Mitigation Strategies for False-Negatives:

• Test multiple antigen retrieval methods

• Include phosphatase inhibitors throughout sample preparation

• Use signal amplification methods for low-abundance targets

• Include positive control samples with known TGFBR1 expression

Properly validated experimental workflows drastically reduce the risk of both false-positive and false-negative results when working with TGFBR1 antibodies .

How should researchers validate a new lot of TGFBR1 (Ab-165) Antibody to ensure consistency with previous experiments?

Lot-to-lot validation is critical for experimental reproducibility:

Essential Validation Steps:

• Western blot comparison: Run new and old antibody lots side-by-side

• Titration experiments: Determine optimal concentration for the new lot

• Positive control panel: Test across multiple cell lines/tissues with known TGFBR1 expression

• Signal-to-noise assessment: Compare background levels between lots

• Phospho-specificity check: Verify detection of phosphorylated vs. non-phosphorylated forms

Documentation Requirements:

• Record lot numbers, dilutions, and incubation conditions

• Photograph/scan original blots and staining results

• Document any protocol adjustments needed for the new lot

• Maintain validation samples for future comparisons

Acceptance Criteria:

• Consistent banding pattern at expected molecular weight (~56 kDa)

• Comparable signal intensity at equivalent antibody concentrations

• Similar background levels

• Equivalent specificity in immunoprecipitation experiments

Thorough validation enables confident comparison of results obtained with different antibody lots and maintains experimental reproducibility over time .

How can researchers accurately quantify TGFBR1 expression levels across multiple experimental conditions?

Accurate quantification of TGFBR1 across experimental conditions requires rigorous methodology:

Western Blot Quantification:

• Include loading controls (β-actin, GAPDH) and normalize TGFBR1 signals

• Use housekeeping proteins with expression stability in your experimental context

• Apply LI-COR or similar quantitative detection systems for broader dynamic range

• Run standard curves with recombinant protein for absolute quantification

Immunofluorescence Quantification:

• Perform all staining in parallel with identical parameters

• Use automated image acquisition with consistent exposure settings

• Apply threshold-based or machine learning segmentation algorithms

• Report integrated intensity values normalized to cell number or area

RT-qPCR Quantification:

• Design primers spanning exon-exon junctions

• Validate primer efficiency using standard curves

• Use multiple reference genes for normalization

• Calculate relative expression using the 2^-ΔΔCt method

Flow Cytometry Approaches:

• Include calibration beads for consistent instrument settings

• Report results as median fluorescence intensity

• Use isotype controls to set negative thresholds

• Consider cell permeabilization optimization for intracellular domains

Integrating multiple quantification approaches provides comprehensive understanding of TGFBR1 regulation at transcriptional, translational, and post-translational levels .

How is TGFBR1 (Ab-165) Antibody being used to investigate the role of receptor phosphorylation in modulating signaling outcomes?

Current research is utilizing TGFBR1 (Ab-165) Antibody to explore how phosphorylation states influence signaling:

Advanced Applications:

• Mapping temporal dynamics of phosphorylation events following ligand binding

• Correlating Ser165 phosphorylation with receptor activation and downstream signaling

• Investigating phosphorylation-dependent protein-protein interactions

• Identifying kinases and phosphatases that regulate TGFBR1 phosphorylation state

Methodological Approaches:

• Phospho-specific vs. total receptor antibodies: Compare phosphorylation ratios

• Proximity ligation assays: Detect phosphorylation-dependent interactions in situ

• Mass spectrometry: Identify novel phosphorylation sites and quantify stoichiometry

• Live-cell imaging: Monitor phosphorylation dynamics in real-time with phospho-sensors

Research Insights:
Research has demonstrated that phosphorylation status influences receptor stability and signaling duration. For example, studies using proteasome inhibitors revealed that TGFBR1 degradation is regulated by ubiquitination patterns, which are in turn influenced by phosphorylation status. This provides a mechanistic link between receptor phosphorylation, stability, and signaling persistence .

What are the current challenges and advancements in using TGFBR1 antibodies for single-cell analysis techniques?

Single-cell analysis of TGFBR1 presents both challenges and opportunities:

Current Challenges:

• Limited sensitivity for detecting low-abundance receptors

• Maintaining phospho-epitope integrity during single-cell processing

• Distinguishing membrane-bound from internalized receptors

• Correlation of protein levels with functional signaling outcomes

Technical Advancements:

• Single-cell Western blotting: Emerging technique for protein analysis at single-cell resolution

• Mass cytometry (CyTOF): Metal-conjugated antibodies for multiplexed detection

• Imaging mass cytometry: Spatial context with single-cell resolution

• Single-cell RNA-seq with protein detection: Correlating transcriptome with surface proteins

Methodological Considerations:

• Careful validation of antibody specificity at single-cell level

• Development of signal amplification strategies for low-abundance targets

• Implementation of machine learning algorithms for automated analysis

• Integration of multiple parameters for comprehensive signaling assessment

These techniques promise deeper understanding of TGFBR1 heterogeneity across cell populations and within tumor microenvironments, potentially revealing novel therapeutic vulnerabilities .